Following WHO’s 100% cure announcement for Buruli ulcer, Qurient starts an additional 바카라 배팅 법 trial for 80 people in Australia
[by Kang, In Hyo] Qurient, a company specializing in the development of innovative novel drugs, announced on July 9 that it has begun enrolling an additional 80 participants for the Australian clinical trial of ‘Telacebec’ targeting Buruli ulcer, following the initial cohort of 40 patients. This clinical trial represents an extension of the first study conducted between July and December 2024, with the trial design and participating countries remaining unchanged.
TB Alliance, the organization leading the development of 바카라 배팅 법, presented interim results from the first clinical trial at the World Health Organization (WHO) International Conference held in March in Geneva, Switzerland. According to the findings, 바카라 배팅 법 attracted significant attention for demonstrating an exceptionally high safety profile and a near 100% cure rate, with minimal side effects even after a short treatment duration. Given its mechanism of selectively targeting specific mycobacteria, similar outcomes are anticipated in the ongoing expanded clinical trial.
Telacebec has been granted ‘orphan drug’ designation by the U.S. Food and Drug Administration (FDA) for the treatment of Buruli ulcer. This designation allows the drug to be submitted for regulatory approval on comparatively limited clinical data, thereby offering favorable conditions that may expedite the development and approval procedures.
“Expectations for regulatory approval have greatly increased following the interim results released earlier this year. If the efficacy and safety demonstrated in the initial trial are consistently replicated in this expanded trial, we anticipate securing key data necessary for the FDA approval application,” a Qurient official said. “Upon approval of the new drug, the value of the Priority Review Voucher (PRV) is expected to increase further, potentially exceeding KRW 300 billion (approximately USD 218.5 million).”
Conversely, the market 바카라 배팅 법 of PRVs has been showing a sharp rise amid growing expectations of reduced supply following the confirmed sunset date of the Rare Pediatric Disease Program (September 2026). Since the second half of 2024, PRV prices have increased by approximately 70% and are currently trading at around USD 160 million (approximately USD 220 billion). Historically, PRVs have been traded at prices as high as USD 350 million.